XSTO
STIL
Market cap198mUSD
Jun 10, Last price
212.00SEK
1D
0.00%
1Q
-9.79%
Jan 2017
362.88%
Name
Stille AB
Chart & Performance
Profile
Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 569,950 93.27% | 294,893 19.70% | 246,350 31.68% | |||||||
Cost of revenue | 457,782 | 252,400 | 216,722 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 112,168 | 42,493 | 29,628 | |||||||
NOPBT Margin | 19.68% | 14.41% | 12.03% | |||||||
Operating Taxes | 10,964 | 4,939 | 5,479 | |||||||
Tax Rate | 9.77% | 11.62% | 18.49% | |||||||
NOPAT | 101,204 | 37,554 | 24,149 | |||||||
Net income | 58,206 118.44% | 26,646 -2.48% | 27,324 69.75% | |||||||
Dividends | (9,024) | (5,013) | ||||||||
Dividend yield | 1.19% | 0.89% | ||||||||
Proceeds from repurchase of equity | 209,219 | 205,000 | ||||||||
BB yield | -11.17% | -27.05% | ||||||||
Debt | ||||||||||
Debt current | 24,876 | 12,966 | ||||||||
Long-term debt | 65,224 | 83,404 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 165,460 | 37,008 | 32,214 | |||||||
Net debt | (158,485) | (151,346) | 59,693 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 73,535 | 37,277 | 31,936 | |||||||
CAPEX | (2,321) | (1,408) | (8,042) | |||||||
Cash from investing activities | (330,315) | (12,903) | (8,042) | |||||||
Cash from financing activities | 171,400 | 178,993 | (18,539) | |||||||
FCF | 263,150 | (187,011) | 14,289 | |||||||
Balance | ||||||||||
Cash | 158,485 | 241,446 | 36,677 | |||||||
Long term investments | ||||||||||
Excess cash | 129,988 | 226,701 | 24,360 | |||||||
Stockholders' equity | 149,900 | 121,681 | ||||||||
Invested Capital | 864,865 | 582,304 | 266,830 | |||||||
ROIC | 13.99% | 8.85% | 9.49% | |||||||
ROCE | 12.97% | 5.67% | 9.56% | |||||||
EV | ||||||||||
Common stock shares outstanding | 9,008 | 5,018 | 5,013 | |||||||
Price | 208.00 37.75% | 151.00 34.82% | 112.00 -25.58% | |||||||
Market cap | 1,873,754 147.29% | 757,730 34.94% | 561,510 -25.58% | |||||||
EV | 1,715,269 | 606,384 | 621,203 | |||||||
EBITDA | 112,168 | 56,850 | 39,274 | |||||||
EV/EBITDA | 15.29 | 10.67 | 15.82 | |||||||
Interest | 15,573 | 10,099 | 2,336 | |||||||
Interest/NOPBT | 13.88% | 23.77% | 7.88% |